Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for Radiotherapy-induced Heart Damage in Lung Tumor Patients
NCT04939857Phase 3Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trimetazidine in Cardiotoxicity (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Global Longitudinal Strain. Status: unknown.
02
Drugs
trimetazidine
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT04939857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939857.